Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

NCT05946122•Minia University

View on ClinicalTrials.gov

Summary

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Eligibility

Age

25 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients ( male and female) with systemic inflammatory response ( total leucocytic count \>12,000 mm3'. temperature \>38 C, Heart rate \>90 b/min and respiratory rate\>20 cycle).

Exclusion Criteria

•Hemodynamic instability
•Pre-admission chronic kidney disease.
•Intra-vascular coagulopathy
•Patients with myopathy.

Locations (1)

Mina Maher Raouf

Minya, Minia University, Egypt

Key Dates

Start Date

May 30, 2023

Primary Completion Date

December 12, 2023

Completion Date

December 30, 2023

Last Updated

July 14, 2023

Enrollment

106

ESTIMATED participants

Conditions

Renal Protection

Interventions

Atorvastatin 40 Mg Oral Tablet

DRUG

placebo drug

DRUG

Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery

NCT06521697

Head and Neck CancerAnesthesia+3 more

View study

UNKNOWN

Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

NCT00497666

DiabetesDiabetic Nephropathy+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions